Hitting the golden TORget: Curcumin's effects on mTOR signaling

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 7, 2013, Pages 988-994

  Beevers, Christopher S ^a   Zhou, Hongyu ^b   Huang, Shile ^c,d  

^a ROSS UNIVERSITY SCHOOL OF MEDICINE   (Dominica)

^b KUNMING INSTITUTE OF BOTANY   (China)

^c Department of Biochemistry and Molecular Biology ^*  (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Akt; Cancer; Cell death; Cell proliferation; Curcumin; mTOR

Indexed keywords

CURCUMIN; EPIGALLOCATECHIN GALLATE; GLUTATHIONE TRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE C;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; ANGIOGENESIS; ARTICLE; AUTOPHAGY; BLADDER CANCER; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG SAFETY; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CURCUMIN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84882784220     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313070004     Document Type: Article

References (100)

1. Sharma, R. A.; Gescher, A. J.; Steward, W. P. Curcumin: the story so far. Eur. J. Cancer, 2005, 41, 1955-1968.
2. Aggarwal, B. B.; Kumar, A.; Bharti, A. C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 2003, 23, 363-398.
3. Jovanovic, S. V.; Boone, C. W.; Steenken, S.; Trinoga, M.; Kaskey, R. B. How curcumin works preferentially with water soluble antioxidants. J. Am. Chem. Soc., 2001, 123, 3064-3068.
4. Tonnesen, H. H.; Karlsen, J. Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution. Z. Lebensm. Unters. Forsch., 1985, 180, 402-404.
5. Shankar, T. N.; Shantha, N. V.; Ramesh, H. P.; Murthy, I. A.; Murthy, V. S. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs & monkeys. Indian J. Exp. Biol., 1980, 18, 73-75.
6. Cheng, A. L.; Hsu, C. H. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 2001, 21, 2895-2900.
7. Sharma, R. A.; McLelland, H. R.; Hill, K. A.; Ireson, C. R.; Euden, S. A.; Manson, M. M.; Pirmohamed, M.; Marnett, L. J.; Gescher, A. J.; Steward, W. P. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res., 2001, 7, 1894-1900.
8. Anand, P.; Kunnumakkara, A. B.; Newman, R. A.; Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol. Pharm., 2007, 4, 807-818.
9. Sharma, R. A.; Steward, W. P.; Gescher, A. J. Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol., 2007, 595, 453-470.
10. Beevers, C. S.; Huang, S. Pharmacological and clinical properties of curcumin. Botanics: Targets and Therapy, 2011, 1, 5-18.
11. Basnet, P.; Skalko-Basnet, N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules, 2011, 16, 4567-4598.
12. Zhou, H.; Beevers, C. S.; Huang, S. The targets of curcumin. Curr. Drug Targets, 2011, 12, 332-347.
13. Gupta, S. C.; Kim, J. H.; Prasad, S.; Aggarwal, B. B. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev., 2010, 29, 405-434.
14. Deodhar, S. D.; Sethi, R.; Srimal, R. C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J. Med. Res., 1980, 71, 632-634.
15. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F. M.; Torti, S. V. Curcumin: from ancient medicine to current clinical trials. Cell Mol. Life Sci., 2008, 65, 1631-1652.
16. Dhillon, N.; Aggarwal, B. B.; Newman, R. A.; Wolff, R. A.; Kunnumakkara, A. B.; Abbruzzese, J. L.; Ng, C. S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res., 2008, 14, 4491-4499.
17. Sharma, R. A.; Euden, S. A. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res., 2004, 10, 6847-6854.
18. Kuttan, R.; Sudheeran, P. C.; Josph, C. D. Turmeric and curcumin as topical agents in cancer therapy. Tumori, 1987, 73, 29-31.
19. Hanif, R.; Qiao, L.; Shiff, S. J.; Rigas, B. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandinindependent pathway. J. Lab. Clin. Med., 1997, 130, 576-584.
20. Beevers, C. S.; Li, F.; Liu, L.; Huang, S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int. J. Cancer, 2006, 119, 757-764.
21. Dennis, P. B.; Jaeschke, A.; Saitoh, M.; Fowler, B.; Kozma, S. C.; Thomas, G. Mammalian TOR: a homeostatic ATP sensor. Science, 2001, 294, 1102-1105.
22. Hara, K.; Yonezawa, K.; Kozlowski, M. T.; Sugimoto, T.; Andrabi, K.; Weng, Q. P.; Kasuga, M.; Nishimoto, I.; Avruch, J. Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem., 1997, 272, 26457-26463.
23. Kim, D. H.; Sarbassov, D. D.; Ali, S. M.; King, J. E.; Latek, R. R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D. M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 2002, 110, 163-175.
24. Zhou, H.; Huang, S. The complexes of mammalian target of rapamycin. Curr. Protein Pept. Sci., 2011, 11, 409-424.
25. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev., 2004, 18, 1926-1945.
26. Beevers, C. S.; Chen, L.; Liu, L.; Luo, Y.; Webster, N. J.; Huang, S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res., 2009, 69, 1000-1008.
27. Johnston, S. R. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. Int. J. Gynecol. Cancer, 2006, 16 Suppl 2, 543-548.
28. LeRoith, D.; Roberts, C. T., Jr. The insulin-like growth factor system and cancer. Cancer Lett., 2003, 195, 127-137.
29. Carver, D. J.; Aman, M. J.; Ravichandran, K. S. SHIP inhibits Akt activation in B cells through regulation of Akt membrane localization. Blood, 2000, 96, 1449-1456.
30. Kohn, A. D.; Takeuchi, F.; Roth, R. A. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J. Biol. Chem., 1996, 271, 21920-21926.
31. Frias, M. A.; Thoreen, C. C.; Jaffe, J. D.; Schroder, W.; Sculley, T.; Carr, S. A.; Sabatini, D. M. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol., 2006, 16, 1865-1870.
32. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307, 1098-1101.
33. Pearce, L. R.; Huang, X.; Boudeau, J.; Pawlowski, R.; Wullschleger, S.; Deak, M.; Ibrahim, A. F.; Gourlay, R.; Magnuson, M. A.; Alessi, D. R. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J., 2007, 405, 513-522.
34. Peterson, R. T.; Desai, B. N.; Hardwick, J. S.; Schreiber, S. L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc. Natl. Acad. Sci. U. S. A., 1999, 96, 4438-4442.
35. Garami, A.; Zwartkruis, F. J.; Nobukuni, T.; Joaquin, M.; Roccio, M.; Stocker, H.; Kozma, S. C.; Hafen, E.; Bos, J. L.; Thomas, G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell, 2003, 11, 1457-1466.
36. Long, X.; Lin, Y.; Ortiz-Vega, S.; Yonezawa, K.; Avruch, J. Rheb binds and regulates the mTOR kinase. Curr. Biol., 2005, 15, 702-713.
37. Long, X.; Ortiz-Vega, S.; Lin, Y.; Avruch, J. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J. Biol. Chem., 2005, 280, 23433-23436.
38. Kim, D. H.; Sarbassov, D. D.; Ali, S. M.; Latek, R. R.; Guntur, K. V.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D. M. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell, 2003, 11, 895-904.
39. Sancak, Y.; Thoreen, C. C.; Peterson, T. R.; Lindquist, R. A.; Kang, S. A.; Spooner, E.; Carr, S. A.; Sabatini, D. M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell, 2007, 25, 903-915.
40. Dufner, A.; Thomas, G. Ribosomal S6 kinase signaling and the control of translation. Exp. Cell Res., 1999, 253, 100-109.
41. Pullen, N.; Thomas, G. The modular phosphorylation and activation of p70s6k. FEBS Lett., 1997, 410, 78-82.
42. Weng, Q. P.; Kozlowski, M.; Belham, C.; Zhang, A.; Comb, M. J.; Avruch, J. Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J. Biol. Chem., 1998, 273, 16621-16629.
43. Pause, A.; Belsham, G. J.; Gingras, A. C.; Donze, O.; Lin, T. A.; Lawrence, J. C., Jr.; Sonenberg, N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature, 1994, 371, 762-767.
44. Raught, B.; Peiretti, F.; Gingras, A. C.; Livingstone, M.; Shahbazian, D.; Mayeur, G. L.; Polakiewicz, R. D.; Sonenberg, N.; Hershey, J. W. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. Embo J., 2004, 23, 1761-1769.
45. Shahbazian, D.; Roux, P. P.; Mieulet, V.; Cohen, M. S.; Raught, B.; Taunton, J.; Hershey, J. W.; Blenis, J.; Pende, M.; Sonenberg, N. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. Embo J., 2006, 25, 2781-2791.
46. Holz, M. K.; Ballif, B. A.; Gygi, S. P.; Blenis, J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell, 2005, 123, 569-580.
47. Gingras, A. C.; Raught, B.; Sonenberg, N. Regulation of translation initiation by FRAP/mTOR. Genes Dev., 2001, 15, 807-826.
48. Gingras, A. C.; Raught, B.; Gygi, S. P.; Niedzwiecka, A.; Miron, M.; Burley, S. K.; Polakiewicz, R. D.; Wyslouch-Cieszynska, A.; Aebersold, R.; Sonenberg, N. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev., 2001, 15, 2852-2864.
49. Tokunaga, C.; Yoshino, K.; Yonezawa, K. mTOR integrates amino acid-and energy-sensing pathways. Biochem. Biophys. Res. Commun., 2004, 313, 443-446.
50. Sarbassov, D. D.; Sabatini, D. M. Redox regulation of the nutrientsensitive raptor-mTOR pathway and complex. J. Biol. Chem., 2005, 280, 39505-39509.
51. Magagnin, M. G.; van den Beucken, T.; Sergeant, K.; Lambin, P.; Koritzinsky, M.; Devreese, B.; Wouters, B. G. The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency. Proteomics, 2008, 8, 1019-1028.
52. DeYoung, M. P.; Horak, P.; Sofer, A.; Sgroi, D.; Ellisen, L. W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev., 2008, 22, 239-251.
53. Wullschleger, S.; Loewith, R.; Hall, M. N. TOR signaling in growth and metabolism. Cell, 2006, 124, 471-484.
54. Fingar, D. C.; Salama, S.; Tsou, C.; Harlow, E.; Blenis, J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev., 2002, 16, 1472-1487.
55. Liu, L.; Li, F.; Cardelli, J. A.; Martin, K. A.; Blenis, J.; Huang, S. Rapamycin inhibits cell motility by suppression of mTORmediated S6K1 and 4E-BP1 pathways. Oncogene, 2006, 25, 7029-7040.
56. Edinger, A. L.; Thompson, C. B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell, 2002, 13, 2276-2288.
57. Huang, S.; Shu, L.; Easton, J.; Harwood, F. C.; Germain, G. S.; Ichijo, H.; Houghton, P. J. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J. Biol. Chem., 2004, 279, 36490-36496.
58. Inoki, K.; Corradetti, M. N.; Guan, K. L. Dysregulation of the TSCmTOR pathway in human disease. Nat. Genet., 2005, 37, 19-24.
59. Tee, A. R.; Blenis, J. mTOR, translational control and human disease. Semin. Cell Dev. Biol., 2005, 16, 29-37.
60. Kwiatkowski, D. J. Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet., 2003, 67, 87-96.
61. Manning, B. D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol., 2004, 167, 399-403.
62. Dann, S. G.; Selvaraj, A.; Thomas, G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med., 2007, 13, 252-259.
63. Thedieck, K.; Polak, P.; Kim, M. L.; Molle, K. D.; Cohen, A.; Jeno, P.; Arrieumerlou, C.; Hall, M. N. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One, 2007, 2, e1217.
64. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell, 2007, 12, 9-22.
65. Rubio-Viqueira, B.; Hidalgo, M. Targeting mTOR for cancer treatment. Adv. Exp. Med. Biol., 2006, 587, 309-327.
66. Guertin, D. A.; Stevens, D. M.; Thoreen, C. C.; Burds, A. A.; Kalaany, N. Y.; Moffat, J.; Brown, M.; Fitzgerald, K. J.; Sabatini, D. M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell, 2006, 11, 859-871.
67. Polak, P.; Hall, M. N. mTORC2 Caught in a SINful Akt. Dev. Cell, 2006, 11, 433-434.
68. Peng, T.; Golub, T. R.; Sabatini, D. M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell Biol., 2002, 22, 5575-5584.
69. Mayer, C.; Grummt, I. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene, 2006, 25, 6384-6391.
70. Roos, S.; Jansson, N.; Palmberg, I.; Saljo, K.; Powell, T. L.; Jansson, T. Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. J. Physiol., 2007, 582, 449-459.
71. Ramirez-Valle, F.; Braunstein, S.; Zavadil, J.; Formenti, S. C.; Schneider, R. J. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J. Cell Biol., 2008, 181, 293-307.
72. Mammucari, C.; Schiaffino, S.; Sandri, M. Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy, 2008, 4, 524-526.
73. Shinojima, N.; Yokoyama, T.; Kondo, Y.; Kondo, S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumininduced autophagy. Autophagy, 2007, 3, 635-637.
74. Martin, D. E.; Hall, M. N. The expanding TOR signaling network. Curr. Opin. Cell Biol., 2005, 17, 158-166.
75. Mayer, C.; Zhao, J.; Yuan, X.; Grummt, I. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev., 2004, 18, 423-434.
76. Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Ruegg, M. A.; Hall, A.; Hall, M. N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol., 2004, 6, 1122-1128.
77. Sarbassov, D. D.; Ali, S. M.; Kim, D. H.; Guertin, D. A.; Latek, R. R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D. M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol., 2004, 14, 1296-1302.
78. Garcia-Martinez, J. M.; Alessi, D. R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J., 2008, 416, 375-385.
79. Plas, D. R.; Thompson, C. B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem., 2003, 278, 12361-12366.
80. Li, Y.; Tennekoon, G. I.; Birnbaum, M.; Marchionni, M. A.; Rutkowski, J. L. Neuregulin signaling through a PI3K/Akt/Bad pathway in Schwann cell survival. Mol. Cell Neurosci., 2001, 17, 761-767.
81. Wan, X.; Helman, L. J. The biology behind mTOR inhibition in sarcoma. Oncologist, 2007, 12, 1007-1018.
82. Wan, X.; Harkavy, B.; Shen, N.; Grohar, P.; Helman, L. J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene, 2007, 26, 1932-1940.
83. Hosoi, H.; Dilling, M. B.; Shikata, T.; Liu, L. N.; Shu, L.; Ashmun, R. A.; Germain, G. S.; Abraham, R. T.; Houghton, P. J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res., 1999, 59, 886-894.
84. Li, M.; Zhang, Z.; Hill, D. L.; Wang, H.; Zhang, R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res., 2007, 67, 1988-1996.
85. Aoki, H.; Takada, Y.; Kondo, S.; Sawaya, R.; Aggarwal, B. B.; Kondo, Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol. Pharmacol., 2007, 72, 29-39.
86. Johnson, S. M.; Gulhati, P.; Arrieta, I.; Wang, X.; Uchida, T.; Gao, T.; Evers, B. M. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res., 2009, 29, 3185-3190.
87. Lim, H. W.; Lim, H. Y.; Wong, K. P. Uncoupling of oxidative phosphorylation by curcumin: implication of its cellular mechanism of action. Biochem. Biophys. Res. Commun., 2009, 389, 187-192.
88. Rafiee, P.; Binion, D. G.; Wellner, M.; Behmaram, B.; Floer, M.; Mitton, E.; Nie, L.; Zhang, Z.; Otterson, M. F. Modulatory effect of curcumin on survival of irradiated human intestinal microvascular endothelial cells: role of Akt/mTOR and NF-{kappa}B. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 298, G865-877.
89. Clark, C. A.; McEachern, M. D.; Shah, S. H.; Rong, Y.; Rong, X.; Smelley, C. L.; Caldito, G. C.; Abreo, F. W.; Nathan, C. O. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma. Cancer Prev. Res. (Phila), 2010, 3, 1586-1595.
90. Sun, Z. J.; Chen, G.; Zhang, W.; Hu, X.; Liu, Y.; Zhou, Q.; Zhu, L. X.; Zhao, Y. F. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-kappaB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IkappaB kinase complex signaling axis in adenoid cystic carcinoma. Mol. Pharmacol., 2011, 79, 106-118.
91. Leonhard, W. N.; van der Wal, A.; Novalic, Z.; Kunnen, S. J.; Gansevoort, R. T.; Breuning, M. H.; de Heer, E.; Peters, D. J. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am. J. Physiol. Renal Physiol., 2011, 300, F1193-1202.
92. Wong, T. F.; Takeda, T.; Li, B.; Tsuiji, K.; Kitamura, M.; Kondo, A.; Yaegashi, N. Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition. Gynecol. Oncol., 2011, 122, 141-148.
93. Kondo, A.; Takeda, T.; Li, B.; Tsuiji, K.; Kitamura, M.; Wong, T. F.; Yaegashi, N. Epigallocatechin-3-gallate potentiates curcumin's ability to suppress uterine leiomyosarcoma cell growth and induce apoptosis. Int. J. Clin. Oncol., 2012, [Epub ahead of print]
94. Phillips, J. M.; Clark, C.; Herman-Ferdinandez, L.; Moore-Medlin, T.; Rong, X.; Gill, J. R.; Clifford, J. L.; Abreo, F.; Nathan, C. O. Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo. Otolaryngol. Head Neck Surg., 2011, 145, 58-63.
95. Chen, T.; Shen, L.; Yu, J.; Wan, H.; Guo, A.; Chen, J.; Long, Y.; Zhao, J.; Pei, G. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell, 2011, 10, 908-911.
96. Yu, S.; Shen, G.; Khor, T. O.; Kim, J. H.; Kong, A. N. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol. Cancer Ther., 2008, 7, 2609-2620.
97. Millward, T. A.; Zolnierowicz, S.; Hemmings, B. A. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem. Sci., 1999, 24, 186-191.
98. Westphal, R. S.; Coffee, R. L., Jr.; Marotta, A.; Pelech, S. L.; Wadzinski, B. E. Identification of kinase-phosphatase signaling modules composed of p70 S6 kinase-protein phosphatase 2A (PP2A) and p21-activated kinase-PP2A. J. Biol. Chem., 1999, 274, 687-692.
99. Nanahoshi, M.; Nishiuma, T.; Tsujishita, Y.; Hara, K.; Inui, S.; Sakaguchi, N.; Yonezawa, K. Regulation of protein phosphatase 2A catalytic activity by alpha4 protein and its yeast homolog Tap42. Biochem. Biophys. Res. Commun., 1998, 251, 520-526.
100. Dey, R.; Majumder, N.; Bhattacharjee, S.; Majumdar, S. B.; Banerjee, R.; Ganguly, S.; Das, P.; Majumdar, S. Leishmania donovani-induced ceramide as the key mediator of Akt dephosphorylation in murine macrophages: role of protein kinase Czeta and phosphatase. Infect. Immun., 2007, 75, 2136-2142.